ClinicalTrials.gg
CompletedNCT06323174REIMAGINE 1Updated Sep 30, 2026

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

A Phase 3 interventional study of Cagrilintide and Semaglutide in Type 2 Diabetes, sponsored by Novo Nordisk A/S. Completed at 50 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.

Enrollment
10th of 15
189 · median 274
Started
2024
with 5 others
Phase 3
10 of 15
3 open now
Registered
6th of 15
by date
Lead sponsor
15 of 15
Novo Nordisk A/S

Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 6 that started in 2024, is one of 10 in phase 3, and was the 6th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age 18 years or above at the time of signing the
  • Diagnosed with type 2 diabetes >=30 days before screening
  • 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
  • (BMI) >=23 kilograms per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using a highly effective method
  • Renal impairment with estimated less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m\^2) as determined by central laboratory at screening
  • Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
189 participants (actual)

Study arms

  • Active comparator
    CagriSema Dose 2

    Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Placebo comparator
    Placebo Dose 2

    Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks.

    Drug: Placebo

  • Active comparator
    Cagrisema Dose 1

    Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Placebo comparator
    Placebo Dose 1

    Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks.

    Drug: Placebo

Interventions

  • Participants will receive once-weekly cagrilintide subcutaneously.

  • Participants will receive once-weekly semaglutide subcutaneously.

  • DrugPlacebo

    Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

06

What researchers measure

Primary outcomes

  1. Change in glycated haemoglobin (HbA1c)

    Measured as percentage (%)-points.

    Time frame: From baseline (week 0) to end of treatment (week 40)

Secondary outcomes

  1. Relative change in body weight

    Measured in %.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  2. Number of participants who achieve greater than or equal to (>=) 10% body weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  3. Number of participants who achieve >=15% body weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  4. Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])

    Measured as count of participants.

    Time frame: At end of treatment (week 40)

  5. Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)

    Measured as count of participants.

    Time frame: At end of treatment (week 40)

  6. Change in Fasting Plasma Glucose (FPG)

    Measured in millimoles per liter (mmol/L).

    Time frame: From baseline (week 0) to end of treatment (week 40)

  7. Number of participants who achieve >=5% body weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  8. Number of participants who achieve >=20% body weight reduction

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  9. Change in waist circumference

    Measured in centimeters (cm).

    Time frame: From baseline (week 0) to end of treatment (week 40)

  10. Change in systolic blood pressure (SBP)

    Measured in millimeters of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 40)

  11. Change in diastolic blood pressure (DBP)

    Measured in mmHg.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  12. Ratio to baseline in high sensitivity C-reactive protein (hsCRP)

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  13. Ratio to baseline in lipids: Total cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  14. Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  15. Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  16. Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  17. Ratio to baseline in lipids: Triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  18. Ratio to baseline in lipids: Free fatty acids

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  19. Ratio to baseline in lipids: Non-HDL cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  20. Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)

    Measured as count of participants.

    Time frame: At end of study (week 52)

  21. Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  22. Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score

    Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  23. Change in SF-36v2 score: Physical Component Summary score

    Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  24. Change in SF-36v2 score: Mental Component Summary score

    Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  25. Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score

    Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36).

    Time frame: From baseline (week 0) to end of treatment (week 40)

  26. Change in leptin

    Measured in nanograms per milliliter (ng/mL).

    Time frame: From baseline (week 0) to end of treatment (week 40)

  27. Change in soluble leptin receptor

    Measured in ng/mL.

    Time frame: From baseline (week 0) to end of treatment (week 40)

  28. Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of treatment +7 weeks (week 47)

  29. Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter

    Measured as count of episodes.

    Time frame: From baseline (week 0) to end of treatment +7 weeks (week 47)

  30. Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of episodes.

    Time frame: From baseline (week 0) to end of treatment + 7 weeks (week 47)

07

Study locations

50 sites
  • Nat Res Inst Huntington Park
    Huntington Park, California 90255, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Southern California Dermatology
    Santa Ana, California 92701, United States
  • Encore Medical Research LLC
    Hollywood, Florida 33024, United States
  • Headlands Research Orlando
    Orlando, Florida 32819, United States
  • Encore Medical Research of Weston
    Weston, Florida 33331, United States
  • Alliance for Multispec Res
    Newton, Kansas 67114, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Arcturus HC PLC Troy Med Res
    Troy, Michigan 48098, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • Summit Research Network Oregon Inc.
    Portland, Oregon 97210, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Amarillo Medical Specialists
    Amarillo, Texas 79124, United States
  • Elligo Clin Res Centre
    Austin, Texas 78704, United States
  • Headlands Research Brownsville
    Brownsville, Texas 78526, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • Northeast Clinical Research of San Antonio
    San Antonio, Texas 78233, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Sugar Lakes Family Practice PA
    Sugar Land, Texas 77479, United States
  • Valley Diab. & Endo Comp Ctr
    Weslaco, Texas 78596, United States
  • TPMG Clinical Research
    Newport News, Virginia 23606, United States
  • Chinese People's Liberation Army General Hospital-Endocrinology
    Beijing, Beijing Municipality 100853, China
  • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
    Nanjing, Jiangsu 210011, China
  • The Affiliated Hospital of Jiangsu University-Endocrinology
    Zhenjiang, Jiangsu 212001, China
  • Jinan Central Hospital
    Ji'Nan, Shandong 250000, China
  • Jinan Central Hospital
    Jinan, Shandong 250000, China
  • Belinus Bt.
    Debrecen, Hajdú-Bihar 4025, Hungary
  • Borbánya Praxis E.Ü. Kft.
    Nyíregyháza, Szabolcs-Szatmar Varmegye 4405, Hungary
  • Szent Margit Rendelőintézet Nonprofit Kft.
    Budapest, 1032, Hungary
  • PVN Kutató Kft.
    Budapest, 1102, Hungary
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Policlinico Mater Domini Università di Catanzaro
    Catanzaro, 88100, Italy
  • IRCCS Ospedale San Raffaele Milano
    Milan, 20132, Italy
  • Azienda Ospealiero Universitaria Policlinico Umberto I
    Roma, 00161, Italy
  • Centrum Medyczne Medyk Sp. z o.o.
    Rzeszów, Podkarpackie Voivodeship 35-055, Poland
  • Osteo-Medic s.c. A. Racewicz, J. Supronik
    Bialystok, 15-351, Poland
  • Renew Clinic Sp. z o.o.
    Bialystok, 15-797, Poland
  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
    Lodz, 90-338, Poland
  • NBR Polska Tomasz Klodawski
    Warsaw, 00-710, Poland
  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
    Warsaw, 02-507, Poland
  • Velocity Nova Sp. z o.o.
    Zamość, 22-400, Poland
  • King Abdulaziz Hospital-Al Ahsa-National Guard
    Al Ahsa, 36428, Saudi Arabia
  • National Guard Hospital - Jeddah
    Jeddah, 21423, Saudi Arabia
  • King Fahad Medical City
    Riyadh, 11525, Saudi Arabia
  • King Khaled University Hospital,King Saud Univ. Med. City
    Riyadh, 12372, Saudi Arabia
  • King Salman Bin Abdulaziz Hospital
    Riyadh, 12769, Saudi Arabia
  • CHC Zvezdara, Clinical department for endocrinology
    Belgrade, 11000, Serbia
  • Clinical Hospital Center Bezanijska Kosa
    Belgrade, 11080, Serbia
  • Clinical Hospital Centre Zemun
    Belgrade, 11080, Serbia
  • Policlinic for diabetes
    Zaječar, 19000, Serbia
08

References and documents

Publications

  • Aroda VR, Buzzetti R, Dalskov SM, Jain AB, Larsen JH, Mathieu C, Pratley RE, Videmark A, Watt T, Buse JB. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. Lancet Diabetes Endocrinol. 2026 Aug;14(8):649-661. doi: 10.1016/S2213-8587(26)00126-9. Epub 2026 Jun 7. PubMed 42251860 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Oct 2025, 18 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Mar 21, 2024
StartActual
Mar 19, 2024
Primary completionActual
Oct 1, 2025
CompletionActual
Dec 22, 2025
Results delay requested
Sep 28, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, registry dates and references
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 3 other changes: verification date, registry dates and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06323174
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Mar 19, 2024
Primary completion
Oct 1, 2025
Completion
Dec 22, 2025
Last update
Sep 30, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion